557502
Ro-20-1724
≥98% (TLC), solid, cAMP phosphodiesterase inhibitor, Calbiochem
别名:
Ro-20-1724, 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C15H22N2O3
化学文摘社编号:
分子量:
278.35
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
产品名称
Ro-20-1724, A cell-permeable, selective inhibitor of cAMP-specific phosphodiesterase (PDE IV; IC₅₀ = 2 µM).
SMILES string
N1C(CNC1=O)Cc2cc(c(cc2)OC)OCCCC
InChI
1S/C15H22N2O3/c1-3-4-7-20-14-9-11(5-6-13(14)19-2)8-12-10-16-15(18)17-12/h5-6,9,12H,3-4,7-8,10H2,1-2H3,(H2,16,17,18)
InChI key
PDMUULPVBYQBBK-UHFFFAOYSA-N
assay
≥98% (TLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
color
white
solubility
DMSO: 20%
ethanol: 4%
shipped in
ambient
storage temp.
10-30°C
Quality Level
Biochem/physiol Actions
Cell permeable: yes
Primary Target
PDE IV
PDE IV
Product does not compete with ATP.
Reversible: no
Target IC50: 2 µM against PDE IV
Disclaimer
Toxicity: Irritant (B)
General description
A cell-permeable, selective inhibitor of cAMP-specific phosphodiesterase (PDE IV; IC50 = 2 µM). Inhibits superoxide generation and arachidonic-induced platelet aggregation. Also inhibits fMLP-induced neutrophil adhesion to vascular endothelial cells.
Selective inhibitor of cAMP-specific phosphodiesterase (PDE IV, IC50 = 2 µM). Inhibits superoxide generation and arachidonic-induced platelet aggregation. Also inhibits fMLP-induced neutrophil adhesion to vascular endothelial cells.
Other Notes
Derian, C.K., et al. 1995. J. Immunol. 154, 308.
Rubin, L.L., et al. 1991. J. Cell Biol.115, 1725.
Lad, P.M., et al. 1985. Biochim. Biophys. Acta 846, 286.
Bergstrand, H., et al. 1977. Mol. Pharmacol.13, 38.
Rubin, L.L., et al. 1991. J. Cell Biol.115, 1725.
Lad, P.M., et al. 1985. Biochim. Biophys. Acta 846, 286.
Bergstrand, H., et al. 1977. Mol. Pharmacol.13, 38.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Pieter J Gaillard et al.
Methods in molecular biology (Clifton, N.J.), 437, 161-175 (2008-03-29)
Drug delivery across the blood-brain barrier (BBB) is a major obstacle for the development of effective treatments of many central nervous system disorders. Sophisticated cell culture models of the BBB have helped us to identify, characterize, and validate a novel
Mohammad Keyvanloo Shahrestanaki et al.
Research in pharmaceutical sciences, 14(2), 107-114 (2019-10-18)
Diabetes incidence showed ascending trends in recent years indicating urgent need for new therapeutic agents. Extracellular adenosine signaling showed promising results. However, role of its A3 receptor in pancreatic β-cells proliferation and insulin secretion is not well established. Thus, we
Jeff A Beeler et al.
Methods in molecular biology (Clifton, N.J.), 237, 39-53 (2003-09-23)
This chapter outlines methods to purify soluble adenylyl cyclase (AC7) expressed in an Escherichia coli (E. coli) heterologous expression system. Guidelines are provided for constructing the expression plasmids, optimizing expression, culturing, and purifying the proteins. Purification requires two chromatographic steps.
Alejandro Sánchez-Melgar et al.
Frontiers in neuroscience, 15, 702817-702817 (2021-09-21)
Gliomas are the most common and aggressive primary tumors in the central nervous system. The nucleoside adenosine is considered to be one major constituent within the tumor microenvironment. The adenosine level mainly depends on two enzymatic activities: 5'-nucleotidase (5'NT or
Moumita Sarkar et al.
iScience, 25(7), 104527-104527 (2022-06-28)
The post-menopausal state in women is associated with increased cancer incidence, the reasons for which remain obscure. Curiously, increased circulating levels of beta-hCG (human chorionic gonadotropin) (a hormonal subunit linked with tumors of several lineages) are also often observed post-menopause.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持